All patients are receiving the therapeutic combination of Immutep’s lead product candidate eftilagimod alpha (“efti” or “IMP321”) with KEYTRUDA® (or pembrolizumab, ananti-PD-1 therapy) at clinical trial sites across the U.S., Europe and Australia.
Immutep CSO and CMO, Dr Frederic Triebel said: “We are pleased with the recruitment of patients in theTACTI-002 clinical trial to date. After dosing the first patient in March this year, we already have 32 patients on study. In addition, we are encouraged by the early signals of efficacy seen in the more advanced part A of the study that appear to be consistent with the synergistic efficacy seen in combining efti with pembrolizumab in the TACTI-mel clinical trial. We very much look forward to presenting more detailed and more mature data at the 34th Annual Meeting of SITC in November.”
AboutTACTI-002
TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). The study is evaluating the combination of Immutep’s lead product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA®(or pembrolizumab, ananti-PD-1 therapy) in up to 109 patients with second line head and neck squamous cell carcinoma ornon-small cell lung cancer in first and second line. The trial is a Phase II, Simon’stwo-stage,non-comparative, open-label,single-arm, multicentre clinical study that is taking place in up to 13 study centres across the U.S., Europe and Australia.
About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a solubleLAG-3Ig fusion protein based on theLAG-3 immune control mechanism, is abest-and-first-in-class MHC II agonist. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC; a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada) referred to asTACTI-002 (Two ACTive Immunotherapies) to evaluate a combination of efti with KEYTRUDA® (or pembrolizumab, ananti-PD-1 therapy) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. referred to asINSIGHT-004 to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869). Immutep is also developing abest-and-first-in-classLAG-3 agonist monoclonal antibody for autoimmune diseases (IMP761) that is currently in preclinical development.
